Yüklüyor......
Development of substituted pyrido[3,2-d]pyrimidines as potent and selective dihydrofolate reductase inhibitors for pneumocystis pneumonia infection
Pneumocystis pneumonia (PCP) caused by Pneumocystis jirovecii (pj) can lead to serious health consequences in patients with an immunocompromised system. Trimethoprim (TMP), used as first-line therapy in combination with sulfamethoxazole, is a selective but only moderately potent pj dihydrofolate red...
Kaydedildi:
| Yayımlandı: | Bioorg Med Chem Lett |
|---|---|
| Asıl Yazarlar: | , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6588427/ https://ncbi.nlm.nih.gov/pubmed/31176699 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bmcl.2019.06.004 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|